Through the 90-day period concluding January 10, 2026, Nurix Therapeutics's top three insider stakeholders include TenPercentOwner Rock Ventures Iii, L.P. Third (3.42Mn shares), TenPercentOwner Group L P Column (1.44Mn shares), Chief Scientific Officer Gwenn Hansen (76.75K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Rock Ventures Iii, L.P. Third | 3,422,549 | 10 May, 2021 | |
| Group L P Column | 1,442,739 | 07 May, 2021 | |
| Gwenn Hansen | Chief Scientific Officer | 76,751 | 30 Oct, 2025 |
| Christine Ring | Chief Legal Officer | 50,897 | 18 Dec, 2025 |
| Houte Hans Van | Chief Financial Officer | 37,592 | 03 Nov, 2025 |
| Julia P Gregory | 10,750 | 17 Sep, 2025 | |
| Stefani Wolff | Evp And Coo | 6,113 | 02 May, 2023 |
| Pierre Beaurang | Chief Business Officer | 4,330 | 11 Aug, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 18 Dec, 2025 | Christine Ring | Common Stock | A | 3,760 | $1.86 | 54,657 | D | M |
| 18 Dec, 2025 | Christine Ring | Common Stock | D | 3,560 | $17.87 | 51,097 | D | S |
| 18 Dec, 2025 | Christine Ring | Common Stock | D | 200 | $18.56 | 50,897 | D | S |
| 24 Nov, 2025 | Christine Ring | Common Stock | A | 37,600 | $1.86 | 88,497 | D | M |
| 24 Nov, 2025 | Christine Ring | Common Stock | D | 37,600 | $17.07 | 50,897 | D | S |
| 03 Nov, 2025 | Houte Hans Van | Common Stock | D | 6,284 | $12.56 | 37,592 | D | S |
| 30 Oct, 2025 | Gwenn Hansen | Common Stock | A | 3,207 | $0.00 | 72,230 | D | M |
| 30 Oct, 2025 | Gwenn Hansen | Common Stock | D | 4,087 | $12.80 | 76,751 | D | S |
| 30 Oct, 2025 | Gwenn Hansen | Common Stock | A | 3,750 | $0.00 | 77,980 | D | M |
| 30 Oct, 2025 | Gwenn Hansen | Common Stock | A | 2,000 | $0.00 | 74,230 | D | M |
| 30 Oct, 2025 | Gwenn Hansen | Common Stock | A | 2,858 | $0.00 | 80,838 | D | M |
| 30 Oct, 2025 | Christine Ring | Common Stock | A | 2,858 | $0.00 | 54,541 | D | M |
| 30 Oct, 2025 | Christine Ring | Common Stock | A | 2,000 | $0.00 | 47,933 | D | M |
| 30 Oct, 2025 | Christine Ring | Common Stock | A | 3,750 | $0.00 | 51,683 | D | M |
| 30 Oct, 2025 | Christine Ring | Common Stock | D | 3,644 | $12.80 | 50,897 | D | S |
| 30 Oct, 2025 | Christine Ring | Common Stock | A | 1,924 | $0.00 | 45,933 | D | M |
| 30 Oct, 2025 | Houte Hans Van | Common Stock | A | 2,000 | $0.00 | 40,398 | D | M |
| 30 Oct, 2025 | Houte Hans Van | Common Stock | A | 2,858 | $0.00 | 47,006 | D | M |
| 30 Oct, 2025 | Houte Hans Van | Common Stock | D | 3,130 | $12.80 | 43,876 | D | S |
| 30 Oct, 2025 | Houte Hans Van | Common Stock | A | 3,750 | $0.00 | 44,148 | D | M |